齐拉西酮与利培酮治疗首发儿童青少年精神分裂症对照研究

A control study of ziprasidone vs. risperidone in the treatment of schizophrenia in children and adolescents

目的探讨齐拉西酮与利培酮治疗首发儿童青少年精神分裂症患者的疗效和安全性。方法将60例首发精神分裂症患者按照随机数字表法分为两组，每组30例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察6周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表评分均较治疗前显著下降（P〈0．01），治疗6周末研究组显效率80．0％、总有效率90．0％，对照组分别为76．7％、90．0％，两组疗效比较差异无显著性（P〉O．05）。两组不良反应均轻微，但研究组体质量增加值及血清泌乳素水平均显著低于对照组（P〈O．01）。结论齐拉西酮与利培酮治疗首发儿童青少年精神分裂症疗效显著且相当，安全性高，但齐拉西酮对体质量及血清泌乳素水平无明显影响，更有利于提高患者的治疗依从性。

Objective To explore the efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia in children and adolescents. Methods Sixty first-episode schizophrenics were assigned to two groups of 30 ones each according to random number table, research group took orally ziprasidone and control did risperidone for 6 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results After treatment the PANSS scores of both groups lowered more significantly compared with pretreatment （P〈0.01）, at the end of the 6th week treatment obvious and total effective rate were respectively 80.0% and 90. 0% in research and 76. 7% and 90.0% in control group, which showed no significant differences （P〉0.05）. Adverse reactions of both groups were mild, but the increase value of weight gain and serum lactotropin level were significantly lower in research than in control group （P〈0.01）. Conclusion Ziprasidon and risperidone are similarly effective and have higher safety in first- episode child and adolescent schizophrenia, but the former has no obvious influence on weight gain and ser- um laetotropin level and is more beneficial to the improvement of patients＇ treatment compliance.